Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD36 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD36 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD36 Products |
| Gene Delivery | CD36 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD36 Products |
| Benchmark Ab | Anti-CD36 (Sequence of Emilasumab) Recombinant positive control. |
View CD36 Products |
| Validator | CD36 siRNA Set For knockdown verification. |
View CD36 Products |
| Related Target A | CD47 Synergistic microenvironmental signaling partner regulating phagocytosis and angiogenesis. |
View CD47 Products |
| Related Target B | SCARB1 Scavenger receptor class B member 1; crucial for off-target selectivity screening. |
View SCARB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation preservation of double-pass membrane protein | Lentivirus Premade Particles optimized for stable cell line generation (Flow Cytometry/Functional Uptake assays) |
| Subfamily counter-screening (SCARB1/SCARB2) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD36 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD36 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeting lipid-mediated immunosuppression and metastasis-initiating cells. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective epitope blocking to prevent lipid uptake without disrupting essential physiological hematological pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Ona Therapeutics, Sanofi | Advanced Solid Tumors, Metastasis | Internalization Assay & Blocking (Need high-purity ECD-Fc & Lentivirus for stable lines) |
| Small Molecules | Mitobridge, Astellas | NASH, CKD, Metabolic Diseases | Selectivity Assay (Need Mutant vs WT Proteins & SCARB1 panel) |
| Bispecific Antibodies | Biotech Startups | Tumor Microenvironment Reprogramming | Heterodimer Validation (Need Cross-reactive Abs & dual-target cell lines) |